Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.46 USD
+0.15 (0.57%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.46 USD
+0.15 (0.57%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors
by Zacks Equity Research
Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors
Exelixis (EXEL) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Exelixis, Inc. (EXEL).
Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?
by Zacks Equity Research
Nutrisystem Inc. (NTRI) is scheduled to release fourth-quarter 2016 results on Feb 27.
Ecolab (ECL): What's in the Cards this Earnings Season?
by Zacks Equity Research
St. Paul, MN-based Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report fourth-quarter 2016 results on Feb 21.
Buy 4 Stocks Riding High on Superb Earnings Acceleration
by Tirthankar Chakraborty
If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be referred to as earnings acceleration.
5 Drug Stocks Poised to Beat Earnings Estimates in Q4
by Arpita Dutt
Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.
DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?
by Zacks Equity Research
York, PA-based DENTSPLY Sirona Inc. (XRAY), a dental solutions company, is expected to report fourth-quarter 2016 results on Feb 10.
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
5 Great Biotech Stocks to Buy Now
by Swarup Gupta
Biotechs have stabilized and still offer the potential to deliver substantial returns.
4 Drug Stocks that are Broker Favorites
by Arpita Dutt
Here's a look at 4 drug stocks preferred by analysts who have a deep knowledge and understanding of the industry and its companies.
Exelixis Inks Partnership with Takeda for Cabometyx in Japan
by Zacks Equity Research
Exelixis (EXEL) and Takeda (TKPYY) entered into an exclusive licensing agreement for the commercialization and clinical development of Cabometyx in Japan.
4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
by Arpita Dutt
Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?
4 Biotech Stocks with Bright Prospects in 2017
by Zacks Equity Research
Even as the drug pricing issue continues to plague the biotech sector, investors should find it safe to bet on these top-ranked biotech stocks that also have superb Style Score as markets roll into 2017.
The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen
Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced that it has amended the exclusive collaboration and licensing agreement with its European partner Ipsen.
4 Biotech Stocks that More than Doubled in 2016
by Arpita Dutt
Despite the immense pressure on the sector, there were some biotech stocks that bucked the trend and more than doubled in 2016.
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis
3 Great Stocks to Beat the Biotech Blues
by Arpita Dutt
Are you on the lookout for some good biotech stocks this month? Here are three that warrant a look.
5 Top Performing Biotechnology Stocks of November
by Zacks Equity Research
November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include ARCO, CORT, EXEL, HL and LXP.